A six-month analysis of the pivotal MOMENTUM 3 trial found that patients implanted with the new HeartMate 3 left ventricular assist system (LVAS) had fewer adverse clotting and bleeding events than patients implanted with the control, HeartMate II LVAS. In this randomized, non-blinded study, a multi-institutional team found that 69 percent of the 151 patients who received Abbott's Heartmate 3 survived without any bleeding or clotting-related adverse events, compared to 55 percent of those who received the Heartmate II.
The University of Chicago Medicine opened a new treatment facility in September that will care for patients with life-threatening heart rhythm irregularities and other forms of cardiac disease. The 1,500-square-foot Arrhythmia Technology Suite combines advanced treatment tools with a team of highly specialized clinicians dedicated to the care of patients with abnormal heart rhythms. It is the one of three electrophysiology laboratories, or EP labs, at the medical center's Hyde Park campus. The lab will provide additional space for clinical research projects as well as education projects for physicians and other health care providers.